These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25860238)

  • 1. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
    Higashi M; Tokuhira M; Fujino S; Yamashita T; Abe K; Arai E; Kizaki M; Tamaru J
    Leuk Lymphoma; 2016; 57(1):161-6. PubMed ID: 25860238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
    Yamamoto W; Nakamura N; Tomita N; Takeuchi K; Ishii Y; Takahashi H; Watanabe R; Takasaki H; Motomura S; Kobayashi S; Yokose T; Ishigatsubo Y; Sakai R
    Leuk Lymphoma; 2014 Dec; 55(12):2721-7. PubMed ID: 24528218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen.
    Rimsza LM; Farinha P; Fuchs DA; Masoudi H; Connors JM; Gascoyne RD
    Leuk Lymphoma; 2007 Mar; 48(3):542-6. PubMed ID: 17454596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.
    Ansell SM; Stenson M; Habermann TM; Jelinek DF; Witzig TE
    J Clin Oncol; 2001 Feb; 19(3):720-6. PubMed ID: 11157023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.
    Głowala-Kosińska M; Chwieduk A; Nieckula J; Saduś-Wojciechowska M; Grosicki S; Rusin A; Nowara E; Giebel S
    Eur J Haematol; 2013 Aug; 91(2):122-8. PubMed ID: 23679234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
    Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
    Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker.
    Hasni MS; Berglund M; Yakimchuk K; Guan J; Linderoth J; Amini RM; Enblad G; Okret S
    Leuk Lymphoma; 2017 Feb; 58(2):418-427. PubMed ID: 27357538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
    Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
    Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
    Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
    Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.
    Kawamura K; Wada A; Wang JY; Li Q; Ishii A; Tsujimura H; Takagi T; Itami M; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):27-36. PubMed ID: 26077666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
    Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
    Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
    Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
    Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.